Our Clinical Sites and Trials

A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies

A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with…

Closed to accrual

28 days of intensive follow-up, followed by limited follow-up through 24 weeks.

See locations

A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

About 30-40% of people living with HIV have a condition called NAFLD, or non-alcoholic fatty liver disease.  NAFLD is caused…

Closed to accrual

See locations

A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B

A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral…

Closed to accrual

72 weeks

See locations

A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

Weight gain after starting HIV therapy is common, but recent studies have found that some people with HIV (PWH) who…

Open and enrolling

Participants will be on study treatment for 48 weeks.

See locations

A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART

Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment…

Open and enrolling

Maximum of 2 years. Arm A will receive one dose of N-803 at Week 1 and then every 3 weeks for a total of eight doses.

See locations

A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Vaccine

Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized.…

Closed to accrual

See locations

A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function

Since the early days of the HIV epidemic cytomegalovirus (CMV) has been one of the most common and devastating opportunistic…

Open and enrolling

About 2 years (96 weeks).

See locations

ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT)

This study will include 180 participants. Participants will have HIV and Cytomegalovirus (CMV). CMV is common virus that many people…

Closed to accrual

See locations

A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP)

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.

Open and enrolling

See locations